

## **Developments in Biologicals**

ISSN 1424-6074

### **116 Development of Therapeutic Cancer Vaccines**

Editors: F. Brown, Greenport, NY, U.S.A.; J. Petricciani, Carlsbad, CA, U.S.A.  
XII + 248 p., 44 fig., 9 tab., soft cover 2004. ISBN 3-8055-7736-2

This monograph contains the proceedings of a conference devoted to progress and emerging issues in therapeutic cancer vaccine development since the 1998 FDA/NCI workshop. The emphasis is on progress in the clinical trials of cancer vaccines in late-stage development, but the volume also includes presentations and discussions on exciting earlier-stage products as well as updates on regulatory positions in the USA, Canada, Europe, and Australia.

Session I concentrates on regulatory considerations in cancer vaccine development, including a round table of regulatory agency representatives from North America, Europe, and Australia.

Session II continues with a consideration of several different types of cancer vaccines, including whole cells, cell lysates, multivalent recombinants and peptides.

Session III highlights dendritic cell vaccines and dendritic cells fused to tumour cell vaccines.

Session IV focuses on preventive cancer vaccines for cervical carcinoma and liver cancer and various aspects of the immune response to cancer vaccines.

**KARGER**

## Contents

### *Plenary Session*

History of Tumour Vaccines and Novel Approaches for Preventive Cancer Vaccines

*O. Finn*

Are Cancer Vaccines Really the Same as Infectious Disease Vaccines?

*J. Petricciani*

### *Introductory Overviews*

Keynote Address

*P. Noguchi*

Combinatorial Vaccine Strategies and the Use of Molecular Arrays to Characterize T-Cell Activation

*J. Schlom, C. Palena, J.W. Greiner, K.-Y. Tsang, D.W. Grosenbach, H. Sabzevari, J.L. Gulley, P.M. Arlen, E. Kass, J.W. Hodge*

### *Session I*

#### **Regulatory Considerations in Tumour Vaccine Development**

Moderators:      *P. Keegan* (CBER, FDA, USA)

*J. Furesz* (Bureau of Biologics, Canada) *Retired*

*J. Donohoe* (Therapeutic Goods Administration, Australia)

Preclinical Safety Studies in the Development of Tumour Vaccines (Abstract)

*D.M. Essayan*

Regulatory Expectations During Product Development for Tumour Vaccines

*K. Kawakami, R.K. Puri*

Lessons from Preventive Infectious Disease Vaccines

*D.K.F. Chandler, K. Midthun, K.L. Goldenthal*

Clinical Development of Tumour Vaccines (Abstract)

*P. Keegan*

Panel Discussion

### *Session II*

#### **Autologous and Allogeneic: Cellular and Acellular Tumour Vaccines**

Moderators:      *D. Morton* (John Wayne Cancer Institute, USA)

*B.A. Fox* (Earle A. Chiles Research Institute, USA)

*P. Moingeon* (Aventis Pasteur, France)

Characterization of Polyvalent Allogeneic Vaccines

*D. Van Epps*

Defined Antigens and Allogeneic Tumour Lysates as Cancer Vaccines (Abstract)

*M.A. Cheever*

Manipulating the Host Response to Autologous Tumour Vaccines

*J. Ma, C.H. Poehlein, S.M. Jensen, M.G. LaCelle, T.M. Moudgil, D. Rüttinger, D. Haley,*

*M.J. Goldstein, J.W. Smith III, B. Curti, H. Ross, E. Walker, H.M. Hu, W.J. Urba, B.A. Fox*

Autologous Heat Shock Protein-Peptide Complexes for Vaccination Against Cancer: From Bench to Bedside

*A. Hoos, D.L. Levey, J.J. Lewis*

Recombinant Cancer Vaccines Based on Viral Vectors

*P. Moingeon*  
Vaccination of Cancer Patients with Tumour Antigens Recognized by T Lymphocytes (Abstract)  
*T. Boon*  
Characterization of Autologous and Allogeneic Tumour Cells  
*F. Borellini*  
Panel Discussion

### *Session III*

#### **Dendritic Cells (Dc) as Tumour Vaccines**

Moderators: *H. Streicher* (NCI, NIH, USA)  
*U. Kalinke* (Paul-Ehrlich-Institut, Germany)  
*J. Banchereau* (Baylor Institute for Immunology Research, USA)

Dendritic Cells as Melanoma Vaccines  
*J. Banchereau, J. Fay, S. Paczesny, H. Ueno, M. Dhodapkar, A.K. Palucka*  
APC Vaccines: Product Characterization and Clinical Development (Abstract)  
*M.V. Peshwa*  
Clinical Trials with Dendritic Cells: an Update of Product Developments and Clinical Trials (Abstract)  
*J.J. Mule*  
Dendritic Cell/Tumour Fusions Vaccine  
*D. Avigan*  
Therapeutic Vaccine Generated by Electrofusion of Dendritic Cells and Tumour Cells  
*H. Kuriyama, K. Shimizu, W. Lee, J. Kjaergaard, M.R. Parkhurst, P.A. Cohen, S. Shu*  
Panel Discussion

### *Session IV*

#### **Preventive Tumour Vaccines, Clinical Strategies and Immunological Assessment in Early Clinical Trials**

Moderators *I. Gust* (University of Melbourne, Australia)  
*J.S. Robertson* (NIBSC, U.K.)  
*O.J. Finn* (University of Pittsburgh, USA)

E6, E7 and VLP Based Papillomavirus Vaccines for Prevention of Cervical Cancer (Abstract)  
*I. Frazer*  
Hepatitis C Vaccines to Prevent Liver Cancer (Abstract)  
*M. Houghton*  
CoVal™ Fusions: a Therapeutic Vaccine Platform Using Heat Shock Proteins to Treat Chronic Viral Infection and Cancer  
*J.R. Neefe, N.R. Chu, L. Mizzen*  
Immunotherapeutic Strategies for Melanoma: The Role of Anatomic Site in Vaccination and Immune Monitoring (Abstract)  
*P. Hwu*  
Assays for Monitoring a CEA Peptide-Induced Immunological Response in Dendritic Cell Trials (Abstract)  
*H.K. Lyerly*  
Precision Guiding of Cytolytic T-Lymphocyte Responses (Abstract)  
*C.J.M. Melief, H. Dumortier, S. Zwaveling, D. Schuurhuis, G. van Mierlo, J.P. Medema, F. Ossendorp, S. van der Burg, R. Offringa*  
Effective Peptide Vaccines for Melanoma (Abstract)  
*J.S. Weber*  
Immune Response to Postsurgical Adjuvant Active Immunotherapy with Canvaxin Polyvalent Cancer Vaccine: Correlations with Clinical Course of Patients with Metastatic Melanoma  
*D.L. Morton*  
Methods to Monitor Immune Response and Quality Control  
*T.L. Whiteside*  
Panel Discussion